These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 28751451)

  • 1.
    D'Huyvetter M; De Vos J; Xavier C; Pruszynski M; Sterckx YGJ; Massa S; Raes G; Caveliers V; Zalutsky MR; Lahoutte T; Devoogdt N
    Clin Cancer Res; 2017 Nov; 23(21):6616-6628. PubMed ID: 28751451
    [No Abstract]   [Full Text] [Related]  

  • 2. Fluorine-18 Labeling of the HER2-Targeting Single-Domain Antibody 2Rs15d Using a Residualizing Label and Preclinical Evaluation.
    Zhou Z; Vaidyanathan G; McDougald D; Kang CM; Balyasnikova I; Devoogdt N; Ta AN; McNaughton BR; Zalutsky MR
    Mol Imaging Biol; 2017 Dec; 19(6):867-877. PubMed ID: 28409338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluorine-18 labeling of an anti-HER2 VHH using a residualizing prosthetic group via a strain-promoted click reaction: Chemistry and preliminary evaluation.
    Zhou Z; Chitneni SK; Devoogdt N; Zalutsky MR; Vaidyanathan G
    Bioorg Med Chem; 2018 May; 26(8):1939-1949. PubMed ID: 29534937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Labeling Single Domain Antibody Fragments with Fluorine-18 Using 2,3,5,6-Tetrafluorophenyl 6-[
    Zhou Z; McDougald D; Devoogdt N; Zalutsky MR; Vaidyanathan G
    Mol Pharm; 2019 Jan; 16(1):214-226. PubMed ID: 30427188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Efficient Method for Labeling Single Domain Antibody Fragments with
    Zhou Z; Devoogdt N; Zalutsky MR; Vaidyanathan G
    Bioconjug Chem; 2018 Dec; 29(12):4090-4103. PubMed ID: 30384599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis, preclinical validation, dosimetry, and toxicity of 68Ga-NOTA-anti-HER2 Nanobodies for iPET imaging of HER2 receptor expression in cancer.
    Xavier C; Vaneycken I; D'huyvetter M; Heemskerk J; Keyaerts M; Vincke C; Devoogdt N; Muyldermans S; Lahoutte T; Caveliers V
    J Nucl Med; 2013 May; 54(5):776-84. PubMed ID: 23487015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of an
    Feng Y; Meshaw R; McDougald D; Zhou Z; Zhao XG; Jannetti SA; Reiman RE; Pippen E; Marjoram R; Schaal JL; Vaidyanathan G; Zalutsky MR
    Sci Rep; 2022 Feb; 12(1):3020. PubMed ID: 35194100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic Efficacy of
    Dekempeneer Y; Caveliers V; Ooms M; Maertens D; Gysemans M; Lahoutte T; Xavier C; Lecocq Q; Maes K; Covens P; Miller BW; Bruchertseifer F; Morgenstern A; Cardinaels T; D'Huyvetter M
    Mol Pharm; 2020 Sep; 17(9):3553-3566. PubMed ID: 32787284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Labeling of Anti-HER2 Nanobodies with Astatine-211: Optimization and the Effect of Different Coupling Reagents on Their in Vivo Behavior.
    Dekempeneer Y; Bäck T; Aneheim E; Jensen H; Puttemans J; Xavier C; Keyaerts M; Palm S; Albertsson P; Lahoutte T; Caveliers V; Lindegren S; D'Huyvetter M
    Mol Pharm; 2019 Aug; 16(8):3524-3533. PubMed ID: 31268724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical Targeted α- and β
    Puttemans J; Dekempeneer Y; Eersels JL; Hanssens H; Debie P; Keyaerts M; Windhorst AD; van der Aa F; Lecocq Q; Breckpot K; Morgenstern A; Bruchertseifer F; Lahoutte T; Devoogdt N; D'Huyvetter M
    Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32326199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I Trial of
    D'Huyvetter M; Vos J; Caveliers V; Vaneycken I; Heemskerk J; Duhoux FP; Fontaine C; Vanhoeij M; Windhorst AD; Aa FV; Hendrikse NH; Eersels JLE; Everaert H; Gykiere P; Devoogdt N; Raes G; Lahoutte T; Keyaerts M
    J Nucl Med; 2021 Aug; 62(8):1097-1105. PubMed ID: 33277400
    [No Abstract]   [Full Text] [Related]  

  • 12. Evaluation of [
    Ducharme M; Hall L; Eckenroad W; Cingoranelli SJ; Houson HA; Jaskowski L; Hunter C; Larimer BM; Lapi SE
    Mol Pharm; 2023 Sep; 20(9):4629-4639. PubMed ID: 37552575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Labeling single domain antibody fragments with
    Zhou Z; McDougald D; Meshaw R; Balyasnikova I; Zalutsky MR; Vaidyanathan G
    Nucl Med Biol; 2021; 100-101():24-35. PubMed ID: 34146837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Astatine-211 labeled anti-HER2 5F7 single domain antibody fragment conjugates: radiolabeling and preliminary evaluation.
    Choi J; Vaidyanathan G; Koumarianou E; Kang CM; Zalutsky MR
    Nucl Med Biol; 2018 Jan; 56():10-20. PubMed ID: 29031230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Site-specific radioiodination of an anti-HER2 single domain antibody fragment with a residualizing prosthetic agent.
    Feng Y; Zhou Z; McDougald D; Meshaw RL; Vaidyanathan G; Zalutsky MR
    Nucl Med Biol; 2021 Jan; 92():171-183. PubMed ID: 32448731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved tumor targeting of anti-HER2 nanobody through N-succinimidyl 4-guanidinomethyl-3-iodobenzoate radiolabeling.
    Pruszynski M; Koumarianou E; Vaidyanathan G; Revets H; Devoogdt N; Lahoutte T; Lyerly HK; Zalutsky MR
    J Nucl Med; 2014 Apr; 55(4):650-6. PubMed ID: 24578241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of an Anti-HER2 Nanobody Labeled with
    Pruszynski M; D'Huyvetter M; Bruchertseifer F; Morgenstern A; Lahoutte T
    Mol Pharm; 2018 Apr; 15(4):1457-1466. PubMed ID: 29502411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer.
    Vaneycken I; Devoogdt N; Van Gassen N; Vincke C; Xavier C; Wernery U; Muyldermans S; Lahoutte T; Caveliers V
    FASEB J; 2011 Jul; 25(7):2433-46. PubMed ID: 21478264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of an anti-p185(HER2) (scFv-C(H)2-C(H)3)2 fragment following radioiodination using two different residualizing labels: SGMIB and IB-Mal-D-GEEEK.
    Vaidyanathan G; Jestin E; Olafsen T; Wu AM; Zalutsky MR
    Nucl Med Biol; 2009 Aug; 36(6):671-80. PubMed ID: 19647173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical Evaluation of 225Ac-Labeled Single-Domain Antibody for the Treatment of HER2pos Cancer.
    Rodak M; Dekempeneer Y; Wojewódzka M; Caveliers V; Covens P; Miller BW; Sevenois MB; Bruchertseifer F; Morgenstern A; Lahoutte T; D'Huyvetter M; Pruszyński M
    Mol Cancer Ther; 2022 Dec; 21(12):1835-1845. PubMed ID: 36129807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.